Fibromyalgia and Interleukin-2 Therapy for Malignancy
Authors: DANIEL J. WALLACE
Journal: Annals of Internal Medicine (1988)

Letters and Corrections1 June 1988Fibromyalgia and Interleukin-2 Therapy for MalignancyDANIEL J. WALLACE, M.D., KIM MARGOLIN, M.D., PAM WALLER, R.N.DANIEL J. WALLACE, M.D., KIM MARGOLIN, M.D., PAM WALLER, R.N.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-6-909_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the study by Denicoff and colleagues (1) on the neuropsychiatric effects of treatment with interleukin-2 with or without lymphokine-activated killer cells. The authors observed that most patients had decreased energy, fatigue, anorexia, malaise, and sleep disturbances. In neither this report nor the group's most recent toxicity survey is there any mention of musculoskeletal complications, even though such symptoms were briefly discussed previously (2, 3). The City of Hope National Medical Center is one of six collaborating centers using variations of the Rosenberg protocol. Many of the patients we have treated were observed to...References1. DENICOFFRUBINOWPAPA KDM. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987;107:293-300. LinkGoogle Scholar2. ROSENBERGLOTZEMUUL SML. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-97. CrossrefMedlineGoogle Scholar3. LOTZEMATORYETTINGHAUSEN MYS. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL2. J Immunol. 1985;135:2865-75. MedlineGoogle Scholar4. GOLDENBERG D. Fibromyalgia syndrome: An emerging but controversial condition. JAMA. 1987;257:2782-7. CrossrefMedlineGoogle Scholar5. PETERWALLACE JD. Abnormalities in immunologic regulation in the primary fibromyalgia syndrome [Abstract]. Arthritis Rheum. 1988;31: [In press]. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: City of Hope National Medical Center Duarte, CA 91010 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLow-dose interleukin-2 for systemic lupus erythematosus?Principles of Therapy, Local Measures, and NSAIDsIntroductory Chapter: A Challenge to the Concept that Inflammation Plays a Prominent Pathogenic Role in FibromyalgiaInflammation in the pathophysiology of neuropathic painThe Role and Importance of Small Fiber Neuropathy in Fibromyalgia PainCytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosisEditorial: Fibromyalgia: A Never-Ending Story of Central and Peripheral Pain MechanismsEvidence of Abnormal Epidermal Nerve Fiber Density in Fibromyalgia: Clinical and Immunologic ImplicationsBiomarkers in fibromyalgiaFibromyalgia and Myofascial PainPrinciples of Therapy, Local Measures, and Nonsteroidal MedicationsUnique immunologic patterns in fibromyalgiaCytokine-related and histological biomarkers for neuropathic pain assessmentAcupuntura en el manejo complementario de la fibromialgiaMCP-1 and IL-8 as Pain Biomarkers in Fibromyalgia: A Pilot StudyNeuroendocrine immunology of fibromyalgiaPathophysiology of fibromyalgiaIntegrated Review of the Association of Cytokines With Fibromyalgia and Fibromyalgia Core SymptomsThe Role of IL-8 in Patients With FibromyalgiaZytokinregulation und SchmerzFibromyalgia: An update and immunological aspectsStatus of immune mediators in painful neuropathiesStatus of immune mediators in fibromyalgiaAnti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndromeReduced levels of antiinflammatory cytokines in patients with chronic widespread painCytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot studyNeuroendocrine and Immune Aspects of FibromyalgiaThe Fibromyalgia SyndromeLeukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2Sleep, neuroimmune and neuroendocrine functions in fibromyalgia and chronic fatigue syndromeANTIMALARIAL AGENTS AND LUPUSFibromyalgia and Chronic Fatigue SyndromeFibromyalgia: Chronobiological AspectsFibromyalgiaChronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancyPsychiatric Illness in patients with chronic fatigue and those with rheumatoid arthritisToward an integrated understanding of fibromyalgia syndrome. I. Medical and pathophysiological aspectsImmunomodulating agentsCytokines and immune regulation in patients with fibrositisFibromyalgia: The Clinical Syndrome 1 June 1988Volume 108, Issue 6Page: 909-909KeywordsCellsFatigueFibromyalgiaSleepToxicity Issue Published: 1 June 1988 PDF downloadLoading ...